Article Text

Download PDFPDF

O-019 Safety and efficacy of cangrelor use in neurovascular intervention: a multicenter experience
  1. G Cortez1,
  2. A Monteiro1,
  3. N Sourour2,
  4. F Clarençon2,
  5. M Elhoray2,
  6. M Grigoryan3,
  7. S Mirza3,
  8. G Dabus4,
  9. I Linfante4,
  10. Y Murtaza1,
  11. P Aguilar-Salinas5,
  12. A Aghaebrahim1,
  13. E Sauvageau1,
  14. R Hanel1
  1. 1Neurosurgery, Baptist Health System- Jacksonville, Jacksonville, FL
  2. 2Pitié-Salpêtrière Hospital, Paris, FRANCE
  3. 3Adventist Health Glendale Comprehensive Stroke Center, Los Angeles, CA
  4. 4Miami Neuroscience, Cardiac, and Vascular Institute, Baptist Hospital, Miami, FL
  5. 5Neurosurgery, University of Arizona, Tucson, AZ


Introduction/Purpose In patients undergoing acute neurointervention, thromboembolic complications are the most common procedure related morbidity, in special when endoluminal prosthesis (stents/flow diverters) are needed. Dual-antiplatelet therapy (DAPT) has been used in order to prevent these events. Cangrelor is a potent, intravenous, P2Y12-receptor antagonist presented as an alternative to oral antiplatelet agents, with a rapid onset and offset. We aimed to evaluate the safety and effectiveness of cangrelor in patients with acute neurologic ischemic disease and intracranial aneurysms that underwent endovascular intervention.

Materials and Methods We conducted a multicenter retrospective review of patients who underwent acute neurological intervention and had cangrelor as part of their optimal treatment. Patients from four comprehensive interventional neurovascular centers were included and allocated into two groups: (1) Acute ischemic (acute stroke and/or symptomatic atherosclerotic disease) and Aneurysms (ruptured and unruptured). Clinical presentation, laboratorial data, and outcomes were analyzed with an emphasis on periprocedural thromboembolic and hemorrhagic complications.

Results A total of 66 patients were included, 42 of whom were allocated in the ischemic group and 24 in the aneurysm group. In the acute ischemic group, median NIHSS was 15.5 (IQR, 8.25–21], and the majority of patients underwent mechanical thrombectomy (73%) associated with either rescue intracranial stenting (61.3%) or carotid stenting (35.4%). The overall periprocedural complication in this group was 9.5%, corresponding to 3 (7.1%) postoperative symptomatic intracranial hemorrhages (sICH) and 1 (2.3%) intraoperative thromboembolic event. At discharge, a favorable outcome (mRS 0–2) was noted in 47.6%, and 1 (2.4%) patient died after the progression of a sizeable infarct. In the aneurysm group, 66.7% were ruptured, and the most common treatment modality was flow diverter (66.7%). Although overall periprocedural complication was noted in 3 cases (12.5%), only one complication (4.2%) had occurred during or after cangrelor infusion. It consisted of a sICH in previously ruptured aneurysm. The other two complications occurred before cangrelor infusion, being 1 sICH and 1 thromboembolic event. At discharge, a favorable outcome (mRS 0–2) was seen in 66.7%, and mortality was 8.3%, related to the ruptured aneurysms that progressed with sICH. When both groups were divided according to cangrelor infusion duration, there was no significant difference in the number of complications in patients receiving either short (median of 2h hours) or prolonged (median of 24 hours) infusion.

Conclusion Cangrelor is a safe alternative in patients requiring immediate intervention with the use of stents and flow diverters. Cangrelor was not associated with increased rates of hemorrhagic complications and also allowed the possibility for a secure transition to long-term DAPT and progression to surgery in the setting of unexpected complications. Ideally, prospective studies with larger samples and comparison with a standard antiplatelet regimen are required to clarify the best protocol, safety profile, and effectiveness of cangrelor in neurologic endovascular interventions, unlikely to happen on our field.

Disclosures G. Cortez: None. A. Monteiro: None. N. Sourour: None. F. Clarençon: None. M. Elhoray: None. M. Grigoryan: None. S. Mirza: None. G. Dabus: None. I. Linfante: None. Y. Murtaza: None. P. Aguilar-Salinas: None. A. Aghaebrahim: None. E. Sauvageau: None. R. Hanel: 1; C; Chiese USA, Inc. 2; C; Microvention, Codman, Stryker and Medtronic.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.